Cellular Intelligence Expands Leadership Team for Next Growth Phase

Cellular Intelligence, the AI company building a universal foundation model of cell signaling, announced the addition of two senior leaders to its executive team, as it prepares for the next phase of growth. Jonathan Alspaugh, chief strategy officer, joins with over 15 years of experience in biopharma strategy, finance, and operations. Adam Weinroth, chief marketing officer, brings over two decades of experience scaling AI and deep-tech platforms. The appointments expand Cellular Intelligence's leadership at an inflection point in its mission to decode the language of cellular signaling in order to advance novel therapeutic applications.

"We founded Cellular Intelligence on the belief that decoding the language of cellular communication moves us toward a future where biology can be a matter of design, not just destiny. That conviction hasn't changed. What has changed is that we're ready to lay the groundwork for our business strategy and the next stage of our scientific and technology efforts," said Micha Breakstone, Ph.D., Co-Founder and CEO of Cellular Intelligence. "Jonathan and Adam are exactly the leaders to do that. Jonathan builds strategy at the intersection of deep science and capital, and Adam has spent his career creating categories for platforms that redefine their industries."

Alspaugh most recently served as president and chief strategy officer of RyCarma Therapeutics and previously as president and chief financial officer of Aeglea BioTherapeutics, where he led the company's merger with Spyre Therapeutics. Before moving into operating roles, he spent a decade in investment banking, mostly at Evercore, where he advised biopharma companies through mergers, acquisitions, and financings. He brings a combination of technical depth and financial fluency, holding a master's from the Harvard-MIT Division of Health Sciences and Technology, an MBA from the MIT Sloan School of Management, and bachelor's and master's degrees in nuclear engineering and radiological sciences from the University of Michigan.

"Data is the durable advantage in AI. Cellular Intelligence generates cell signaling data to train its foundation model at a scale that positions it in a class of its own. We can also draw data from our own clinical programs," said Alspaugh, referring to the recent STEM-PD acquisition. "CI is pioneering a new paradigm for understanding biology and ultimately developing novel drugs. That is what brought me here and what will continue to attract capital, enable partnerships, and advance breakthrough science."